|Bid||1.55 x 1000|
|Ask||1.83 x 1000|
|Day's Range||1.64 - 1.76|
|52 Week Range||1.34 - 4.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.
Trevena Inc. shares jumped in the extended session Tuesday after the biotech company said the Food and Drug Administration accepted for review a marketing application for its opioid-replacement painkiller. ...
The Chesterbrook, Pennsylvania-based company said it had a loss of 27 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Chester County biopharmaceutical company Trevena Inc. is cutting 21 jobs and halting its investments in early-stage research under a restructuring to focus its resources on its lead new drug candidate. The workforce reduction represents 30 percent of the Chesterbook, Pa., company's staff. Trevena's immediate focus will be on the potential approval and commercialization of Olinvo, its new drug candidate under development as a potential treatment to manage moderate-to-severe acute pain.
The King Of Prussia, Pennsylvania-based company said it had a loss of 35 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
The King Of Prussia, Pennsylvania-based company said it had a loss of 36 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Trevena, Inc. Here are 5 ETFs with the largest exposure to TRVN-US. Comparing the performance and risk of Trevena, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Trevena (TRVN) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
The King Of Prussia, Pennsylvania-based company said it had a loss of 67 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. However things look like they could be different in 2017.